Presentation is loading. Please wait.

Presentation is loading. Please wait.

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Published byHomer Campbell Modified over 6 years ago

Similar presentations

Presentation on theme: "Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,"— Presentation transcript:

1 Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo- controlled, phase 3 studies (A-101-SEBK-301/302)  Leslie S. Baumann, MD, Andrew Blauvelt, MD, MBA, Zoe D. Draelos, MD, Steven E. Kempers, MD, Mary P. Lupo, MD, Joel Schlessinger, MD, Stacy R. Smith, MD, David C. Wilson, MD, Mark Bradshaw, PhD, Esther Estes, MD, MPH, Stuart D. Shanler, MD, FAAD, FACMS  Journal of the American Academy of Dermatology  Volume 79, Issue 5, Pages (November 2018) DOI: /j.jaad Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Seborrheic keratosis. Study design. HP40, Hydrogen peroxide topical solution 40% (w/w); T, treatment; VEH, vehicle. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Seborrheic keratosis (SK). Percentage of patients with 4 of 4 target SKs with a Physician's Lesion Assessment (PLA) score of 0 (A), percentage of patients with 3 of 4 target SKs with a PLA score of 0 (B), mean per-patient percentage of lesions with a PLA score of 0 (C), and mean per-patient percentage of lesions with a PLA score of 1 or lower (D) in study 1 and study 2 at day 106. A and B, Intent-to-treat population; C and D, per-protocol population. HP40, Hydrogen peroxide topical solution 40% (w/w); VEH, vehicle. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Seborrheic keratosis. Patient photographs of target seborrheic keratosis before and after HP40 treatment: female, forehead (A); female, temple (B); male, forehead (C); and male, back (D). PLA, Physician's Lesion Assessment. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Seborrheic keratosis. Percentage of lesions with erythema (A), edema (B), scaling (C), and crusting (D) by severity at baseline and postbaseline visits. Day 1A/22A and Day 1B/22B, before and immediately after treatment on day 1 and 22, respectively. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study  Gregory R. Delost, DO, Maria E. Delost, PhD, Jenifer.

The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study  Gregory R. Delost, DO, Maria E. Delost, PhD, Jenifer.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy of topical application of eosin for ulcerated hemangiomas

Efficacy of topical application of eosin for ulcerated hemangiomas
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.
Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Similar presentations

Ads by Google